CORE--TRANSGENIC AND KNOCKOUT ANIMAL

$250,404P30FY2002CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739 Paper 39737640 Paper 39726772 Paper 39711559 Paper 39711135 Paper 39684443 Paper 39677775 Paper 39677720 Paper 39677022 Paper 39671500 Paper 39671496 Paper 39630148 Paper 39609428 Paper 39604567 Paper 39603869 Paper 39574899 Paper 39564580 Paper 39554114 Paper 39436696 Paper 39400608 Paper 39384405 Paper 39342284 Paper 39321266 Paper 39311710 Paper 39282307 Paper 39266537 Paper 39264810 Paper 39215796 Paper 39201277 Paper 39191549 Paper 39147413 Paper 39139560 Paper 39136655 Paper 39120971 Paper 39091762 Trial NCT05073848 Trial NCT05053737 Trial NCT05006040 Trial NCT04993859 Trial NCT04988490 Trial NCT04973007 Trial NCT04963283 Trial NCT04940468 Trial NCT04925193 Trial NCT04922112 Trial NCT04916990 Trial NCT04882111 Trial NCT04866758 Trial NCT04863092 Trial NCT04634110 Trial NCT04611022 Trial NCT04565457 Trial NCT04558138 Trial NCT04544592 Trial NCT04541407 Trial NCT04535102 Trial NCT04520867 Trial NCT04486573 Trial NCT04471363 Trial NCT04408092 Trial NCT04305366 Trial NCT04300478 Trial NCT04294693 Trial NCT04208243 Trial NCT04092803 Trial NCT04091867 Trial NCT04066218 Trial NCT04042935 Trial NCT04035408 Trial NCT04028167 Trial NCT04028063 Trial NCT04001101 Trial NCT03995082 Trial NCT03976193 Trial NCT03970226 Trial NCT03958565 Trial NCT03900793 Trial NCT03891654 Trial NCT03881098 Trial NCT03781154 Trial NCT03734653 Trial NCT03617679 Trial NCT03325634 Trial NCT01886859 Trial NCT01426334 Trial NCT01232829 Trial NCT00778167 Patent 9434994 Patent 8734778 Patent 8715649 Patent 8343502 Patent 8337830 Patent 8221763 Patent 8153136 Patent 8067559 Patent 7910315 Patent 7595060 Patent 7563447 Patent 7465454 Patent 7083787

Abstract

Description: (Applicant's Description) The Transgenic/Knockout Shared Core Resource is an expansion from the existing transgenic mouse core laboratory to include targeted gene disruption using homologous recombination in embryonic stem (ES) cells and the generation of "knockout" mice. The facility will also support the in vitro differentiation of ES cells. This core, which began operation in 1990, now consists of has an ES cell/targeted gene disruption facility and a microinjection laboratory. The core provides all the necessary services to support the generation, maintenance, breeding and preservation of transgenic and germ line positive knockout mice. Over the past four and one-half years, the transgenic component of this resource has served 25 different Cancer Center Investigators and generated 241 transgenic founders representing 44 constructs. The new ES cell/gene disruption facility has recently generated four germ line positive knockout mouse lines. In addition, the ES cell laboratory provides technical expertise in growth of ES cells and targeted gene disruption using homologous recombination and instruction of investigators in methods of in vitro ES cell differentiation. The core also provides embryo cryopreservation, strain rederivation, training of Cancer Center investigators, their graduate and postdoctoral students in transgenic technology, models and genetics. This component also provides colony management and maintenance, automated pedigree management, and breeding of all transgenic founders, knockout and experimental breeding colonies. The Transgenic/Knockout core presents a comprehensive service available to Cancer Center investigators for manipulation of the mouse genome. The primary goal is to maintain a state-of-the-art Transgenic/Knockout facility in the Cancer Center that is affordable and accessible to investigators for their studies in cancer biology.

View original record on NIH RePORTER →